Praziquantel, (R)-

Summary

Praziquantel, (R)- (CHEMBL1235551) is a phase-3 clinical-stage small molecule (ATC P02BA03); indicated across 2 conditions including schistosomiasis and helminthiasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: P02BA03
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 312.4 Da · C19H24N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1235551
Name	Praziquantel, (R)-
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	445900
ATC	P02BA03
Molecular formula	C19H24N2O2
Molecular weight	312.4
InChIKey	FSVJFNAIGNNGKK-KRWDZBQOSA-N

SMILES: C1CCC(CC1)C(=O)N2C[C@H]3C4=CC=CC=C4CCN3C(=O)C2

IUPAC name: (11bR)-2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one

Also known as: (-)-praziquantel, (r)-(-)-praziquantel, (r)-praziquantel, Arprazicuantel, Arpraziquantel, L-praziquantel, L-pzq, MSC-2499550A, Msc2499550a, MSC2499550A, Praziquantel, (-)-, Praziquantel, (r)-

Patent coverage: 54 distinct patent families (111 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Prelamin-A/C, Thyrotropin receptor, Cytochrome P450 1A2, Cytochrome P450 2C9, Aldehyde dehydrogenase 1A1, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.7	Potency	199.5	nM	CHEMBL_ACT_3636859
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_3925717
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_4620233
CYP2C19	5.3	Potency	5012	nM	CHEMBL_ACT_4015244
CYP2C19	5.3	AC50	5012	nM	CHEMBL_ACT_6069153
CYP2C9	5.1	Potency	7943	nM	CHEMBL_ACT_5069263
CYP1A2	5	AC50	10000	nM	CHEMBL_ACT_6002975

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
schistosomiasis	3	MONDO:0015254	EFO:1001475
helminthiasis	3	MONDO:0004664	EFO:1001342

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02271984	PHASE1	COMPLETED	Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).